Nkarta (NKTX) Competitors $2.21 -0.10 (-4.33%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NKTX vs. CGEM, PHAR, ABUS, EOLS, IMNM, AUTL, LENZ, ERAS, ORIC, and VECTShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Cullinan Therapeutics (CGEM), Pharming Group (PHAR), Arbutus Biopharma (ABUS), Evolus (EOLS), Immunome (IMNM), Autolus Therapeutics (AUTL), LENZ Therapeutics (LENZ), Erasca (ERAS), ORIC Pharmaceuticals (ORIC), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Cullinan Therapeutics Pharming Group Arbutus Biopharma Evolus Immunome Autolus Therapeutics LENZ Therapeutics Erasca ORIC Pharmaceuticals VectivBio Cullinan Therapeutics (NASDAQ:CGEM) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Is CGEM or NKTX more profitable? Cullinan Therapeutics' return on equity of -26.54% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -26.54% -25.32% Nkarta N/A -27.13%-21.67% Does the MarketBeat Community prefer CGEM or NKTX? Nkarta received 18 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 76.92% of users gave Nkarta an outperform vote. CompanyUnderperformOutperformCullinan TherapeuticsOutperform Votes4282.35% Underperform Votes917.65%NkartaOutperform Votes6076.92% Underperform Votes1823.08% Which has more volatility & risk, CGEM or NKTX? Cullinan Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Do analysts rate CGEM or NKTX? Cullinan Therapeutics currently has a consensus price target of $31.67, indicating a potential upside of 216.35%. Nkarta has a consensus price target of $15.00, indicating a potential upside of 578.73%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Cullinan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has stronger earnings and valuation, CGEM or NKTX? Nkarta has lower revenue, but higher earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan Therapeutics$18.94M30.77-$153.16M-$2.84-3.52NkartaN/AN/A-$117.50M-$1.88-1.18 Does the media prefer CGEM or NKTX? In the previous week, Cullinan Therapeutics had 4 more articles in the media than Nkarta. MarketBeat recorded 5 mentions for Cullinan Therapeutics and 1 mentions for Nkarta. Nkarta's average media sentiment score of 1.51 beat Cullinan Therapeutics' score of 1.03 indicating that Nkarta is being referred to more favorably in the news media. Company Overall Sentiment Cullinan Therapeutics Positive Nkarta Very Positive Do insiders and institutionals hold more shares of CGEM or NKTX? 86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 6.1% of Cullinan Therapeutics shares are held by insiders. Comparatively, 8.7% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryNkarta beats Cullinan Therapeutics on 11 of the 17 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.96M$6.54B$5.25B$8.80BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-1.1810.2185.9016.96Price / SalesN/A201.231,085.59118.01Price / CashN/A57.6743.2137.77Price / Book0.404.885.044.89Net Income-$117.50M$154.38M$122.32M$228.40M7 Day Performance-7.53%-5.11%-2.79%-1.79%1 Month Performance-5.56%-3.16%-0.99%0.03%1 Year Performance-75.20%-4.64%23.59%13.56% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.2567 of 5 stars$2.21-4.3%$15.00+578.7%-75.2%$155.96MN/A-1.18140Positive NewsCGEMCullinan Therapeutics2.5117 of 5 stars$10.85-3.0%$31.67+191.9%-5.5%$631.77M$18.94M-3.8230Positive NewsPHARPharming Group2.4722 of 5 stars$9.14-5.9%$27.00+195.4%-23.0%$620.01M$285.75M-35.15280Short Interest ↑Gap UpABUSArbutus Biopharma2.5418 of 5 stars$3.26-0.9%$5.50+68.7%+37.7%$617.74M$6.74M-7.5873News CoverageEOLSEvolus3.9625 of 5 stars$9.71-2.9%$23.00+136.9%-10.2%$614.85M$248.33M-10.67170News CoverageIMNMImmunome1.5821 of 5 stars$9.84-7.2%$28.83+193.0%-28.7%$614.18M$10.13M-1.2140Analyst ForecastShort Interest ↑News CoverageAUTLAutolus Therapeutics3.0891 of 5 stars$2.30-2.5%$10.40+352.2%-69.3%$612.02M$10.09M-1.90330Analyst ForecastShort Interest ↑News CoverageLENZLENZ Therapeutics1.9982 of 5 stars$22.24-4.2%$35.40+59.2%N/A$611.62MN/A0.00110Short Interest ↑News CoverageERASErasca2.7406 of 5 stars$2.15-9.3%$5.70+165.1%-0.5%$607.86MN/A-2.59126ORICORIC Pharmaceuticals3.6075 of 5 stars$8.41+5.7%$18.29+117.4%+15.2%$593.47MN/A-4.6780Analyst ForecastNews CoverageGap UpVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030 Related Companies and Tools Related Companies Cullinan Therapeutics Competitors Pharming Group Competitors Arbutus Biopharma Competitors Evolus Competitors Immunome Competitors Autolus Therapeutics Competitors LENZ Therapeutics Competitors Erasca Competitors ORIC Pharmaceuticals Competitors VectivBio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTX) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
